Caption Management’s AbCellera Biologics ABCL Stock Holding History

Caption Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-88,332	Closed	-$895K	–	1035
2022 Q4	$895K	Buy	88,332 +83,198	+1,621%	+$961K	0.01%	782
2022 Q3	$51K	Buy	+5,134	New	+$56.3K	﹤0.01%	1383
2022 Q1	–	Sell	-70,700	Closed	-$669K	–	1406
2021 Q4	$1.01M	Buy	70,700 +63,700	+910%	+$967K	0.01%	1045
2021 Q3	$140K	Buy	7,000 +6,900	+6,900%	+$122K	﹤0.01%	1385
2021 Q2	$2K	Buy	+100	New	+$2.76K	﹤0.01%	1245

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Caption Management's ABCL Position: Q1 2023 in Review

Caption Management sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 88,332 shares — an estimated $895K sold.

Caption Management first reported a position in ABCL in Q2 2021 and held it in 5 quarters. The position peaked at $1.01M in Q4 2021. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

Caption Management reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
Caption Management sold 88,332 AbCellera Biologics shares in Q1 2023, an estimated $895K.
Caption Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 5 quarters.
Caption Management's AbCellera Biologics position peaked at $1.01M in Q4 2021.
183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Caption Management's 13F filing for Q1 2023, filed 15 May 2023.